Glucose Health Retained Earnings (Accumulated Deficit) 2014-2019 | GLUC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Glucose Health retained earnings (accumulated deficit) from 2014 to 2019. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Glucose Health Retained Earnings (Accumulated Deficit) 2014-2019 | GLUC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$206.3B
Stryker (SYK)	$148B
Boston Scientific (BSX)	$133.7B
EssilorLuxottica (ESLOY)	$111.2B
Medtronic (MDT)	$110.6B
Haleon (HLN)	$44B
Lonza Group Ag (LZAGY)	$42.2B
GE HealthCare Technologies (GEHC)	$37.9B
ResMed (RMD)	$36.6B
Terumo (TRUMY)	$30.3B
Koninklijke Philips (PHG)	$25.5B
Zimmer Biomet Holdings (ZBH)	$22.3B
Insulet (PODD)	$18.7B
Baxter (BAX)	$17B
Smith & Nephew SNATS (SNN)	$11.2B
BellRing Brands (BRBR)	$9.9B
Bio-Rad Laboratories (BIO)	$9.5B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$6.3B
TG Therapeutics (TGTX)	$5.4B
Haemonetics (HAE)	$4.4B
Prestige Consumer Healthcare (PBH)	$4.2B
Perrigo (PRGO)	$3.9B
ICU Medical (ICUI)	$3.9B
Envista Holdings (NVST)	$3.8B
Agios Pharmaceuticals (AGIO)	$3.3B
Neogen (NEOG)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.9B
QuidelOrtho (QDEL)	$2.8B